Evidence map›Paper›PMID 33718117›Full record

ArticleFrontiers in oncology2020

Ten-Year Single Institutional Analysis of Geographic and Demographic Characteristics of Patients Treated With Stereotactic Body Radiation Therapy for Localized Prostate Cancer.

Nima Aghdam, Michael Carrasquilla, Edina Wang, Abigail N Pepin, Malika Danner, Marilyn Ayoob, Thomas Yung, Brian T Collins, Deepak Kumar, Simeng Suy and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Nima AghdamDepartment of Radiation Medicine, Beth Israel Deaconess Medical Center, Boston, MA, United States.
Michael CarrasquillaDepartment of Radiation Medicine, MedStar Georgetown University Hospital, Washington, DC, United States.
Edina WangDepartment of Radiation Medicine, MedStar Georgetown University Hospital, Washington, DC, United States.
Abigail N PepinDepartment of Radiation Medicine, MedStar Georgetown University Hospital, Washington, DC, United States.
Malika DannerDepartment of Radiation Medicine, MedStar Georgetown University Hospital, Washington, DC, United States.
Marilyn AyoobDepartment of Radiation Medicine, MedStar Georgetown University Hospital, Washington, DC, United States.
Thomas YungDepartment of Radiation Medicine, MedStar Georgetown University Hospital, Washington, DC, United States.
Brian T CollinsDepartment of Radiation Medicine, MedStar Georgetown University Hospital, Washington, DC, United States.
Deepak KumarThe Julius L. Chambers Biomedical Biotechnology Research Institute, North Carolina Central University, Durham, NC, United States.
Simeng SuyDepartment of Radiation Medicine, MedStar Georgetown University Hospital, Washington, DC, United States.
Sean P CollinsDepartment of Radiation Medicine, MedStar Georgetown University Hospital, Washington, DC, United States.
Jonathan W LischalkPerlmutter Cancer Center, Langone Medical Center, New York University, New York, NY, United States.
Georgetown University · USMedStar Georgetown University Hospital · USBeth Israel Deaconess Medical Center · USNorth Carolina Central University · USNYU Langone Health · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesStereotactic Body Radiation Therapy (SBRT) offers definitive treatment for localized prostate cancer with comparable efficacy and toxicity to conventionally fractionated radiotherapy. Decreasing the number of treatment visits from over 40 to five may ease treatment burden and increase accessibility for logistically challenged patients. Travel distance is one factor that affects a patient's access to treatment and is often related to geographic location and socioeconomic status. In this study, we review the demographic and geographic factors of patients treated with SBRT for prostate cancer for a single institution with over a decade of experience.

methodsPatient zip codes from one thousand and thirty-five patients were derived from a large, prospectively maintained quality of life database for patients treated for prostate cancer with SBRT from 2008 to 2017. The geospatial distance between the centroid of each zip code to our institution was calculated using the R package Geosphere. Characteristics for seven hundred and twenty-one patients were evaluated at the time of analysis including: race, age, and insurance status. To assess the geographic reach of our institution, we evaluated the demographic features of each zip code using US Census data. Statistical comparisons for these features and their relation to distance traveled for treatment was performed using the Mann-Whitney U test. Finally, an unsupervised learning algorithm was performed to identify distinct clusters of patients with respect to median income, racial makeup, educational level, and rural residency.

resultsPatients traveled from 246 distinct zip codes at a median distance of 11.35 miles. Forty percent of patients were African American, 6.9% resided in a rural region, and 22% were over the age of 75. Using K-means cluster analysis, four distinct patient zip-code groups were identified based on the aforementioned demographic features: Suburban/high-income (45%), Urban (30%), Suburban/low-income (17%), and Rural (8%). For each of the clusters, the average travel distance for SBRT was significantly different at 11.17, 9.26, 11.75, and 40.2 miles, respectively (p-value: <0.001).

conclusionsDistinct demographic features are related to travel distance for prostate SBRT. In our large cohort, travel distance did not prevent uptake of prostate SBRT in African American, elderly or rural patient populations. Prostate SBRT offers a diverse population modern treatment for their localized prostate cancer and particularly for those who live significant distances from a treatment center.

Indexed as

disparities (health)machine learningprostate cancerracialSBRT (stereotactic body radiation therapy)travel distancetreatment burden

Identifiers

PMID33718117
PMCPMC7947279
OpenAlexW3130677384

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.